10-Q: Mosaic ImmunoEngineering Faces Going Concern Doubt

Mosaic ImmunoEngineering reports a critically low cash balance and substantial accumulated deficit, raising significant doubts about its ability to continue operations without immediate additional funding.

Summary

• Mosaic ImmunoEngineering, Inc. (the Company) filed its Form 10-Q for the quarterly period ended June 30, 2026.
• The Company has a cash and cash equivalents balance of $26 as of June 30, 2026, and has not yet generated any revenues.
• There are substantial doubts regarding the Company's ability to continue as a going concern, as its cash on hand is not expected to satisfy operational and capital requirements for the next twelve months.
• Management is actively seeking additional capital through various financing and business development opportunities, including debt financings, equity offerings, and potential partnering arrangements.
• The Company reported a net loss of $177,496 for the three months ended June 30, 2026, and $352,847 for the six months ended June 30, 2026.
• Research and development expenses were $15,608 for the three months and $31,488 for the six months ended June 30, 2026.
• General and administrative expenses were $141,113 for the three months and $280,035 for the six months ended June 30, 2026.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a negative sentiment due to the company's extremely low cash balance, significant accumulated deficit, and ongoing concerns about its ability to continue as a going concern, despite efforts to secure future funding.

Positives

• The company has a clear focus on advancing and commercializing immunotherapies for cancer treatment.
• Management is actively pursuing multiple avenues for capital raising and business development to secure future operations.
• The company has secured license agreements with CWRU and UC San Diego for technology development, although some agreements have faced termination or challenges.
• Disclosure controls and procedures were deemed effective as of June 30, 2026.

Negatives

• The Company has a critically low cash and cash equivalents balance of $26 as of June 30, 2026.
• The Company has not yet generated any revenues.
• There is substantial doubt about the Company's ability to continue as a going concern.
• The Company has an accumulated deficit of $9,879,013 as of June 30, 2026.
• The Company's cash on hand is insufficient to meet operational and capital requirements for the next twelve months.
• There are no current arrangements for additional financing, and no assurance that financing will be available on commercially reasonable terms.
• Any additional equity financing may result in substantial dilution to existing stockholders.
• The Company has accrued significant liabilities, including accounts payable ($183,226) and accrued compensation ($4,488,205) as of June 30, 2026.

Risks

• The inability to obtain additional capital will delay or cease business operations.
• Any additional equity financing may involve substantial dilution to existing stockholders.
• The Company's limited cash position has required it to perform only limited development activities and delay/scale back development programs.
• Disruptions caused by COVID-19, inflation, or a potential recession may adversely impact the Company's ability to fund future operations.
• The Company may be involved in various lawsuits and claims arising in the ordinary course of business, which could have a material adverse effect.
• The Company has not recorded any liability for potential obligations related to escrowed shares from the Crossflo acquisition, but there is no assurance of a favorable resolution.
• The Company's ability to continue operations is highly dependent on its ability to raise capital.

Future Outlook

The Company anticipates that its current cash on hand will not satisfy its operational and capital requirements through twelve months from the filing date. Management is actively pursuing financing and business development opportunities, but there are significant uncertainties regarding the availability and terms of any future capital. Failure to secure additional capital could lead to curtailment or cessation of operations.

Management Comments

• Management is actively engaged in discussions with potential investors and strategic partners and is pursuing a range of financing and business development opportunities that may include debt financings, equity offerings, and potential partnering arrangements.
• There are a number of uncertainties associated with our ability to raise additional capital and we have no current arrangements with respect to any additional financing.
• Consequently, there can be no assurance that any additional financing on commercially reasonable terms, or at all, will be available when needed.
• If adequate funds are not available on acceptable terms, or at all, the Company will need to curtail operations, or cease operations completely.
• The above matters raise substantial doubt regarding our ability to continue as a going concern.

Industry Context

StockSavvy.ai notes that Mosaic ImmunoEngineering operates in the highly competitive and capital-intensive biotechnology sector, where early-stage companies often face significant challenges in securing funding to advance product candidates through clinical development and regulatory approval. The current financial situation of the company, with minimal cash and substantial accumulated deficit, is a common but critical hurdle for many development-stage biotechs.

Comparison to Industry Standards

• Development-stage biotechnology companies typically require substantial and ongoing capital infusions to fund research, clinical trials, and regulatory processes. Mosaic ImmunoEngineering's current cash position of $26 is significantly below the typical runway required for such endeavors, even for smaller companies.
• Companies in this sector often rely on venture capital, strategic partnerships, or public offerings to fund operations. The failure of the Oncotelic Therapeutics binding term sheet to materialize and the lack of current financing arrangements highlight a deviation from typical industry pathways for securing necessary capital.
• The significant accumulated deficit of nearly $10 million is not uncommon for companies in the biotech sector that are pre-revenue, but it underscores the critical need for successful future financing rounds to avoid insolvency.

Legal Proceedings

• While the Company is not involved in any litigation as of June 30, 2026, it may be involved in various lawsuits and claims arising in the ordinary course of business, including actions with respect to intellectual property, employment, and contractual matters.

Related Party Transactions

• Consulting agreements with Nicole Steinmetz, Ph.D., Jonathan Pokorski, Ph.D., and Steve Fiering, Ph.D. for scientific contributions, with deferred compensation potentially convertible to RSUs upon future financing.
• Investments in convertible notes by former and current Board members, totaling $225,000 from three former Board members in the May Note Agreement and $155,000 from one current and four former Board members in the February Note Agreement.
• Mr. Steven King, President and CEO, is a shareholder and member of the board of directors of Oncotelic Therapeutics, Inc., with less than 1% ownership, and a paid advisor of Oncotelic.

Stakeholder Impact

• Shareholders face significant dilution risk if equity financing is pursued.
• Shareholders face the risk of complete loss of investment if the company cannot secure funding and ceases operations.
• Employees may face uncertainty regarding job security due to the precarious financial situation and potential curtailment of operations.
• Creditors and suppliers may face delays or non-payment of outstanding amounts due to the company's liquidity crisis.

Next Steps

• Secure additional capital through debt financings, equity offerings, or partnering arrangements.
• Continue to fund losses from operations and future funding needs.
• Advance research and development efforts for new potential product candidates, provided sufficient capital is raised.
• Reduce current liabilities.

Key Dates

Recommendation

The company's extremely low cash balance, lack of revenue, significant accumulated deficit, and explicit statement of substantial doubt regarding its ability to continue as a going concern, coupled with the failure of previous strategic initiatives like the Oncotelic deal, present an exceptionally high-risk investment profile. Without immediate and substantial capital infusion, the company is at high risk of insolvency, making it an unattractive investment.

Keywords

biotechnology, immunotherapy, cancer, development-stage, financing, going concern, startup, clinical stage